Control Peptide for S9500-21(antiserum) and S9500-21A (affinity purified). 15 aa peptide located near the C-terminus of human synuclein-alpha. Corresponding antibody recognizes a-Synuclein CT. No significant homology is seen with beta-synuclein or with other known proteins. Species homology: Rat, mouse and chicken: 86% Alzheimers Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly. An early step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43aa peptides (beta amyloid1-40, 1-42, and 1-43). Polymerization of b-amyloid (Ab) and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. Ab deposits have also been found to contain 2 additional proteins termed a-synuclein and b-synuclein. The 140aa a-synucleins is identical with non-Ab component (NACP) of AD. The 134aa b-synuclein is homologous to 14kD bovine phosphoneuroprotein 14. Mutations in a-synuclein gene causing a replacement of alanine with a threonine has the potential to cause the protein to misfold. Applications: Suitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot. Other applications not tested. Recommended Dilution: ELISA: 50-100ng of control peptide/well Antibody Blocking: 5-10ug Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -70C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
